CL2012002035A1 - Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras. - Google Patents

Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras.

Info

Publication number
CL2012002035A1
CL2012002035A1 CL2012002035A CL2012002035A CL2012002035A1 CL 2012002035 A1 CL2012002035 A1 CL 2012002035A1 CL 2012002035 A CL2012002035 A CL 2012002035A CL 2012002035 A CL2012002035 A CL 2012002035A CL 2012002035 A1 CL2012002035 A1 CL 2012002035A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
compounds
disorders
treatment
cardipvascular
Prior art date
Application number
CL2012002035A
Other languages
English (en)
Inventor
Holger Wagner
Daniela Berta
Klaus Fuchs
Riccardo Giovannini
Dieter Wolgang Hamprecht
Ingo Konetzi
Ruediger Streicher
Thomas Trieselmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2012002035A1 publication Critical patent/CL2012002035A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos derivados de furo[3,4-c]quinolin-9-ol y sus sales, inhibidores de CETP; proceso para preparar dichos compuestos; composición farmacéutica y su proceso de preparación; y su uso para el tratamiento o prevención de enfermedades, trastornos o afecciones cardiovasculares, cardiometabólicos o relacionados.
CL2012002035A 2010-02-19 2012-07-20 Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras. CL2012002035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10154086 2010-02-19

Publications (1)

Publication Number Publication Date
CL2012002035A1 true CL2012002035A1 (es) 2013-02-01

Family

ID=43877277

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002035A CL2012002035A1 (es) 2010-02-19 2012-07-20 Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras.

Country Status (22)

Country Link
US (2) US20120053197A1 (es)
EP (1) EP2536733B1 (es)
JP (1) JP5780528B2 (es)
KR (1) KR20130000379A (es)
CN (1) CN102869667A (es)
AP (1) AP2012006390A0 (es)
AR (1) AR080228A1 (es)
AU (1) AU2011217206A1 (es)
BR (1) BR112012020591A2 (es)
CA (1) CA2790643A1 (es)
CL (1) CL2012002035A1 (es)
CO (1) CO6592112A2 (es)
EA (1) EA201201160A1 (es)
EC (1) ECSP12012157A (es)
MA (1) MA34007B1 (es)
MX (1) MX2012009149A (es)
PE (1) PE20121743A1 (es)
SG (1) SG183321A1 (es)
TN (1) TN2012000418A1 (es)
TW (1) TW201139445A (es)
UY (1) UY33229A (es)
WO (1) WO2011101424A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109549A1 (en) 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
AP2012006390A0 (en) 2010-02-19 2012-08-31 Boehringer Ingelheim Int Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2675811A1 (en) * 2011-02-17 2013-12-25 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
WO2013024130A1 (en) * 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US20130210851A1 (en) * 2011-08-18 2013-08-15 Boehringer Ingelheim International Gmbh Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
CN103866646B (zh) * 2014-03-21 2015-10-28 湖南中烟工业有限责任公司 一种生产无酮转移卡纸的工艺
CN103882766B (zh) * 2014-03-21 2015-10-28 湖南中烟工业有限责任公司 一种除去包装卡纸中酮类物质的除酮添加剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798619A (en) 1980-06-02 1989-01-17 American Cyanamid Co. 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents
US4475407A (en) 1982-12-27 1984-10-09 Brunswick Corporation Temperature compensated flow sensor
CH664578A5 (de) * 1985-01-15 1988-03-15 Ciba Geigy Ag Ringsubstituierte 4-azaphthalide.
KR900701792A (ko) 1988-08-16 1990-12-04 로버어트 에이 아미테이지 Acat 효소를 차단하는데 효과적인 이가 리간드
TR199800531T1 (xx) 1995-09-29 1998-06-22 Glaxo Wellcome Spa NMDA antagonistleri olarak tetrahidrokinolinler.
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
HUP0004935A3 (en) 1997-09-04 2001-12-28 Basf Ag Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ATE361273T1 (de) 1998-09-25 2007-05-15 Monsanto Co Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6677341B2 (en) 1999-09-23 2004-01-13 Pharmacia Corporation (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US6448295B1 (en) 1999-09-23 2002-09-10 G.D. Searle & Co. Use of substituted N-fused-phenyl-N-benzyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10238243A1 (de) * 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN1942428A (zh) 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
DE102004060997A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Chemische Verbindung und ihre Verwendung
BRPI0519566A2 (pt) 2004-12-18 2009-01-27 Bayer Healthcare Ag derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp
PL1828137T3 (pl) * 2004-12-18 2012-09-28 Bayer Pharma AG 4-cykloalkilo-podstawione pochodne tetrahydrochinoliny i ich zastosowanie jako leki
JP2008201760A (ja) 2007-02-22 2008-09-04 Tokyo Univ Of Agriculture & Technology 光学活性スピロ化合物及びその製造方法
WO2009109549A1 (en) 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
AP2012006390A0 (en) 2010-02-19 2012-08-31 Boehringer Ingelheim Int Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2675811A1 (en) 2011-02-17 2013-12-25 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
WO2013024130A1 (en) 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US20130210851A1 (en) 2011-08-18 2013-08-15 Boehringer Ingelheim International Gmbh Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative

Also Published As

Publication number Publication date
MA34007B1 (fr) 2013-02-01
CA2790643A1 (en) 2011-08-25
UY33229A (es) 2011-09-30
EA201201160A1 (ru) 2013-04-30
CO6592112A2 (es) 2013-01-02
BR112012020591A2 (pt) 2017-10-10
EP2536733A1 (en) 2012-12-26
MX2012009149A (es) 2012-09-28
AU2011217206A1 (en) 2012-08-02
PE20121743A1 (es) 2012-12-22
KR20130000379A (ko) 2013-01-02
WO2011101424A1 (en) 2011-08-25
TN2012000418A1 (en) 2014-01-30
SG183321A1 (en) 2012-09-27
JP2013519709A (ja) 2013-05-30
ECSP12012157A (es) 2012-10-30
CN102869667A (zh) 2013-01-09
US9029544B2 (en) 2015-05-12
JP5780528B2 (ja) 2015-09-16
AR080228A1 (es) 2012-03-21
AP2012006390A0 (en) 2012-08-31
US20120053197A1 (en) 2012-03-01
TW201139445A (en) 2011-11-16
US20120046304A1 (en) 2012-02-23
EP2536733B1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
CL2012002035A1 (es) Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras.
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
PE20142335A1 (es) Sintesis de compuestos heterociclicos
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
CL2014001174A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
WO2013173441A3 (en) Enhancer of zeste homolog 2 inhibitors
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
ECSP16074478A (es) Compuestos novedosos
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
CO6491034A2 (es) Derivados de amida espirocíclicos
CR20160133A (es) Derivados de fenilalanina sustituidos